Public comment period · §3
Draft monograph: orforglipron — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-ORFORGLIPRON/003 | Dr Abimbola Sotomayor-Ekwueme | Trials are described as terminated where they completed as planned | Accepted in part |
| DRAFT-ORFORGLIPRON/004 | Dr Ulysses Bellingham-Ojo | Evidence for one member of the class is presented as evidence for this compound | Accepted |
| DRAFT-ORFORGLIPRON/005 | Dr Melisande Kirkpatrick-Ola | Declared interests should appear on the document rather than on a separate page | Noted, no amendment |
| DRAFT-ORFORGLIPRON/006 | Dr Thaddeus Isaksen-Balogun | The analytical section assumes a reference standard that is not generally available | Accepted |
| DRAFT-ORFORGLIPRON/007 | Professor Chukwuemeka Rasmussen-Adeyemi | The monograph does not tell a reader that a stated mass may be substantially counter-ion and water | Accepted |
| DRAFT-ORFORGLIPRON/008 | Dr Jerome Lavrentiev | The document set should be published in translation | Not accepted |
| DRAFT-ORFORGLIPRON/002 | Dr Wolfram Tollemache industry | The document should not describe uses outside the approved indication | Not accepted |
| DRAFT-ORFORGLIPRON/009 | Brigitta Grünbaum-Sowande | The pharmacokinetic section does not connect half-life to the dosing schedule | Accepted |
| DRAFT-ORFORGLIPRON/010 | Dr Quentin Zimmerthal | The population to which the headline estimate applies is not stated with the estimate | Accepted |
| DRAFT-ORFORGLIPRON/001 | Dr Wojciech Kaltenbach-Mensah | Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as described | Accepted |
| 10 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 6 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 1 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 1 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 2 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- Trials are described as terminated where they completed as planned — arising from DRAFT-ORFORGLIPRON/003. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
- Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-ORFORGLIPRON/004. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
- The analytical section assumes a reference standard that is not generally available — arising from DRAFT-ORFORGLIPRON/006. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
- The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-ORFORGLIPRON/007. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
- The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-ORFORGLIPRON/009. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
- The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-ORFORGLIPRON/010. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
- Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as… — arising from DRAFT-ORFORGLIPRON/001. Mechanistic claims not traceable to a primary source are removed, and those retained carry their source and a statement of whether the underlying work was conducted in vitro, in animals or in humans.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-030/3 · https://compoundevidence.com/comment-periods/draft-orforglipron-monograph/disposition/ · retrieved 30 July 2026